Your browser doesn't support javascript.
loading
p.P1379S, a benign variant with reduced ATP7B protein level in Wilson Disease.
Yi, Fan; Poskanzer, Sheri A; Myers, Candace T; Thies, Jenny; Collins, Christopher J; Dayuha, Remwilyn; Duong, Phi; Houwen, Roderick; Hahn, Si Houn.
Afiliación
  • Yi F; Seattle Children's Research Institute Seattle Washington USA.
  • Poskanzer SA; Department of Pediatrics University of Washington, School of Medicine Seattle Washington USA.
  • Myers CT; Department of Laboratories Seattle Children's Hospital Seattle Washington USA.
  • Thies J; Biochemical Genetics Seattle Children's Hospital Seattle Washington USA.
  • Collins CJ; Seattle Children's Research Institute Seattle Washington USA.
  • Dayuha R; Seattle Children's Research Institute Seattle Washington USA.
  • Duong P; Seattle Children's Research Institute Seattle Washington USA.
  • Houwen R; Wilhelmina Children's Hospital, Utrecht University Utrecht Netherlands.
  • Hahn SH; Seattle Children's Research Institute Seattle Washington USA.
JIMD Rep ; 54(1): 32-36, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32685348
BACKGROUND: Wilson disease (WD) is an autosomal recessive disorder of copper transport caused by inherited defects in the ATP7B gene and results in toxic accumulation of copper in various organs. We previously reported a family with three consecutive generations affected by WD that carries the variant, p.P1379S, which was classified at the time as likely pathogenic. However, recent investigations of the p.P1379S variant indicate a possible conflict of interpretations regarding its pathogenicity. This led us to explore the quantification of ATP7B in dried blood spots (DBS) using a surrogate peptide to study the effects of the p.P1379S variant on ATP7B concentrations in two unrelated families with the common p.P1379S variant. METHODS AND RESULTS: ATP7B was quantified using the peptide immunoaffinity enrichment coupled with selected reaction monitoring mass spectrometry (immuno-SRM) method which utilizes antibody-mediated peptide capture from DBS. Two patients affected with WD had undetectable ATP7B level while four compound heterozygous children with one known pathogenic variant and the p.P1379S had significantly reduced ATP7B levels. Of note, all four children remain asymptomatic without abnormal laboratory consequences despite being untreated for WD. CONCLUSION: These two families demonstrated that p.P1379S, when compounded with two known pathogenic variants, resulted in significantly reduced protein levels but retained enough function to maintain normal copper homeostasis. This implies that p.P1379S is benign in nature. A better understanding of the nature and consequences of variants in WD will help in informing patient care and avoiding unnecessary treatments.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JIMD Rep Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JIMD Rep Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos